HK inno N Corporation (195940) · Other

Chong Kun Dang Pharm Co (185750) · Earnings Release

Medium importance is estimated based on the potential for significant price movement following the announcement; Q2 2026 earnings release scheduled.

8/18/2026, 12:00:00 AM

Yuhan Corp (000100) · Other

Updated clinical data for 'Leclaza' (lazertinib) from the CHRYSALIS-2 study is scheduled to be presented at the ASCO 2026 conference starting May 29, 2026; medium importance estimated due to potential impact on global market expansion, scheduled.

5/29/2026, 12:00:00 AM

HK inno N Corporation (195940) · Other

Announced on May 22, 2026, that cumulative outpatient prescriptions for K-CAB surpassed 1 trillion KRW; this milestone for the flagship drug is expected to strengthen market leadership.

5/22/2026, 12:00:00 AM

Daewoong Pharmaceutical Co Ltd (069620) · Other

Daewoong Pharmaceutical announced a license-in agreement for a long-acting obesity treatment on 2026-05-21. This entry into the high-growth obesity market is estimated to cause a ≥10% price impact. scheduled

5/21/2026, 12:00:00 AM

Hanmi Pharm Co Ltd (128940) · Other

Announced a 10-year supply contract with Organon worth 52.7 billion KRW to export three combination drugs for cardiovascular and respiratory diseases to Malaysia and the Philippines; low price impact estimated as the annual contract value is small relative to total revenue, scheduled.

5/21/2026, 12:00:00 AM

Yuhan Corp (000100) · Other

Yuhan Corp announced a KRW 210.2 billion API supply agreement with Gilead Sciences on May 20, 2026, effective through December 31, 2027; high importance estimated as the contract value is approximately 11% of annual revenue, scheduled.

5/20/2026, 12:00:00 AM